Related Experiment Video
Updated: Nov 24, 2025
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Daratumumab Interference in Flow Cytometry Producing a False Kappa Light Chain Restriction in Plasma Cells
William Kleinot1, Nadine Aguilera1, Elizabeth L Courville1
1Department of Pathology, University of Virginia Health System, Charlottesville, Virginia, USA.
Daratumumab therapy can cause false kappa light chain restriction in normal cells. This report details a case of pseudo-kappa restriction in cancerous plasma cells, highlighting a diagnostic challenge for pathologists.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Therapeutic anti-CD38 monoclonal antibody daratumumab is used for multiple myeloma.
- False kappa light chain restriction has been observed on normal B-lineage precursors (hematogones) in patients receiving daratumumab.
- This phenomenon can interfere with diagnostic interpretations.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
09:43Analysis of SAMHD1 Restriction by Flow Cytometry in Human Myeloid U937 Cells
Published on: June 13, 2021